Bright Minds Biosciences Inc. (DRUG)
CA — Healthcare Sector
Automate Your Wheel Strategy on DRUG
With Tiblio's Option Bot, you can configure your own wheel strategy including DRUG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DRUG
- Rev/Share 0.0
- Book/Share 7.9197
- PB 5.5235
- Debt/Equity 0.003
- CurrentRatio 88.2725
- ROIC -0.0895
- MktCap 309852124.0691
- FreeCF/Share -0.5886
- PFCF -74.795
- PE -89.6295
- Debt/Assets 0.003
- DivYield 0
- ROE -0.1097
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DRUG | TD Cowen | -- | Buy | -- | -- | May 13, 2025 |
| Initiation | DRUG | Chardan Capital Markets | -- | Buy | -- | $80 | May 7, 2025 |
| Initiation | DRUG | Piper Sandler | -- | Overweight | -- | $93 | Jan. 23, 2025 |
| Initiation | DRUG | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 10, 2025 |
| Initiation | DRUG | H.C. Wainwright | -- | Buy | -- | $85 | Jan. 10, 2025 |
News
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
DRUG
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET.
Read More
About Bright Minds Biosciences Inc. (DRUG)
- IPO Date 2021-03-22
- Website https://brightmindsbio.com
- Industry Biotechnology
- CEO Ian McDonald
- Employees None
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.